Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
This study is currently recruiting patients.
| Sponsored by: | University of Texas Southwestern Medical Center |
| Information provided: | University of Texas Southwestern Medical Center |
| ClinicalTrials.gov Identifier: | NCT00295503 |
Purpose:
To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
| Condition | Intervention | Phase |
|
Mesothelioma |
Drug: bevacizumab Drug: cisplatin Drug: pemetrexed |
Phase 2 |
Eligibility
Study Design: Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Official Title: A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma
Enrollment Size: Both
Gender: 18 Years
Min. Age: N/A
Max. Age: No
Location and Contact Information
United States, Texas
University of Texas Southwestern Medical Center, Dallas, Texas, 75390-8852, United States
Status: Recruiting
Jonathan E Dowell, MD 214-648-7070 jonathan.dowell@utsouthwestern.edu
Last modified: July 29 2010.
